Intended for healthcare professionals


PrEP research: Gilead didn’t infringe patents, jury rules

BMJ 2023; 381 doi: (Published 11 May 2023) Cite this as: BMJ 2023;381:p1079
  1. Bob Roehr
  1. Washington, DC

The drug company Gilead Sciences won on all counts in its legal battle with the US government over control of patents for antiviral drugs for the pre-exposure prophylaxis of HIV infection. The six member jury needed little time to return its verdict in a Delaware courtroom on 9 May.

Scientists at the US Centers for Disease …

View Full Text

Log in

Log in through your institution


* For online subscription